U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT06961214) titled 'Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)' on April 29.
Brief Summary: Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Study Start Date: June 06
Study Type: INTERVENTIONAL
Condition:
Pulmonary Disease, Chronic Obstructive
Intervention:
DRUG: Depemokimab
Depemokimab as a sterile liquid formulat...